CALGARY, AB, March 26, 2021 /CNW/ - Nanalysis Scientific
Corp. ("Nanalysis" or the "Company", TSXV: NSCI, OTCQX: NSCIF, FRA:
1N1) is pleased to announce that the Board of Directors has granted
100,000 stock options to a director of the Company in accordance
with the Company's stock option plan. Each option is exercisable to
purchase one common share of the Company (a "Common Share") at
$0.60 per share, the expiry period is
five years from the date of issuance and the options vest over
three years.
In addition, the Company granted 40,000 restricted share units
("RSUs") to certain directors of the Company pursuant to the
Company's Restricted Share Unit Plan (the "RSU Plan") for a total
of 120,000 RSUs. These RSUs vest in two stages, one-half 18 months
from the date of grant and one-half 36 months from the date of
grant. Each vested RSU entitles the holder to receive one Common
Share. The RSU Plan was approved by the disinterested shareholders
of the Company at the annual general and special meeting held on
June 23,
2020.
About Nanalysis Scientific
Corp. (TSXV: NSCI, OTCQX: NSCIF,
FRA:1N1)
Nanalysis trades on the TSX Venture Exchange (TSXV) in
Canada with ticker symbol 'NSCI'
,Over the Counter (OTC) in the United
States under the ticker symbol 'NSCIF', and on the Frankfurt
Exchange (FRA) under the symbol '1N1'.
Nanalysis is an international business focused on capitalizing
its proprietary technologies in nuclear magnetic resonance (NMR)
that go into NMR spectrometers and magnetic resonance imaging
(MRI). Nanalysis operates out of two subsidiaries, Nanalysis Corp.
and RS2D S.A.S. (RS2D).
Nanalysis Corp. is an industry leader in developing and
manufacturing compact NMR spectrometers for laboratory and
industrial markets. Its cutting edge 60 and 100 MHz spectrometers
require no liquid helium or other cryogens. Its spectrometers are
used by chemical professionals spanning industries, including, but
not limited to, oil and gas, chemical, mining, pharmaceutical, and
biotechnology.
Through its European subsidiary RS2D, the Company electronic
boards and software used to drive MRI equipment in pre-clinical
configurations and are being incorporated into next-gen MRI
systems.
Notice regarding Forward Looking Statements and Legal
Disclaimer
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates", "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed", "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Nanalysis Scientific Corp.